3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio
The gene-editing space has been a hot topic since the end of June. That was when Intellia Therapeutics (NASDAQ: NTLA) and Regeneron Pharmaceuticals (NASDAQ: REGN) released positive phase 1 data from patients who had their DNA edited inside their body. It was the first result to show that the approach could work in humans. The breakthrough sent shares of every gene-editing company soaring. Most have returned to earth, but the excitement is understandable.
Caribou Biosciences (NASDAQ: CRBU) filed its paperwork for an initial public offering (IPO) only days after Intellia's announcement. It was perfectly timed to take advantage of the hype. And there are three reasons it might still be the best gene-editing stock to buy right now.
Image source: Getty Images.
Source Fool.com
